8. ARBS VS ACE INHIBITORS
DO NOT INTERFERE WITH DEGRADATION OF BRADYKININ – COUGH IS RARE
COMPLETE INHIBITION OF AT1 RECEPTOR ACTIVATION
INDIRECT AT2 ACTIVATION
9. INDIVIDUAL DRUGS
LOSARTAN – HIGH FIRST PASS METABOLISM,
NO DOSE ADJUSTMENT – RENAL / LIVER DISEASE
CANDESARTAN – NON COMPETITIVE ANTAGONISM
VALSARTAN – ABSORPTION AFFECTED BY FOOD
OLMESARTAN – NO DOSE ADJUSTMENT
PRODRUG
16. THEORETICAL REASONS
MORE COMPLETE SUPPRESSION OF RAS
ANGIOTENSIN II GENERATED BY ALTERNATE PATHWAYS BLOCKED BY ARBS
ACE INHIBITORS – BRADYKININ RELATED VASODILATATION
ARBS – COMPENSATORY RISE IN ANG II checked by ACEI